Pexidartinib Hydrochloride and Wellbaby DHA
Determining the interaction of Pexidartinib Hydrochloride and Wellbaby DHA and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADJUST DOSING INTERVAL: Coadministration with acid-reducing agents may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown. MANAGEMENT: If acid-suppression therapy is required, pexidartinib should be administered at least 2 hours before or 10 hours after taking an H2-receptor antagonist or 2 hours before or 2 hours after taking a locally-acting antacid. Concomitant use of pexidartinib with proton pump inhibitors should be avoided. References "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Professional:ADJUST DOSING INTERVAL: Coadministration with acid-reducing agents may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown.
MANAGEMENT: If acid-suppression therapy is required, pexidartinib should be administered at least 2 hours before or 10 hours after taking an H2-receptor antagonist or 2 hours before or 2 hours after taking a locally-acting antacid. Concomitant use of pexidartinib with proton pump inhibitors should be avoided.
- "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Generic Name: pexidartinib
Brand name: Turalio
Synonyms: Pexidartinib
Generic Name: omega-3 polyunsaturated fatty acids
Brand name: Proferrin-ES
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Pexidartinib Hydrochloride-Wellbutrin
- Pexidartinib Hydrochloride-Wellbutrin SR
- Pexidartinib Hydrochloride-Wellbutrin Tablets
- Pexidartinib Hydrochloride-Wellbutrin XL
- Pexidartinib Hydrochloride-Wellcovorin
- Pexidartinib Hydrochloride-Wera
- Wellbaby DHA-Pfizerpen
- Wellbaby DHA-Pharaon Tea
- Wellbaby DHA-Pharmorubicin Pfs
- Wellbaby DHA-Phazyme
- Wellbaby DHA-Phazyme Liquid Gas Relief, Maximum Strength
- Wellbaby DHA-Phena-Plus